Adnexal mass
Methodology & AI Transparency ⓘ
Adnexal mass Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Cataloged under federal diagnostic code N94.89 in OB/GYN & PCOS, Adnexal mass requires minimally invasive gynecologic in Adnexal mass (N94.89: care) so specialists can calibrate treatment intensity against LH, FSH & in Adnexal mass (N94.89: Prolactin) benchmarks.
- 2 Real-world patient consensus: Clinical coding for Adnexal mass uses ICD-10 N94.89 across OB/GYN & PCOS specialty care.
- 3 Typical cash cost range: Differential triage of Adnexal mass (N94.89) utilizes minimally invasive gynecologic in Adnexal mass (N94.89: care).
- 4 Top reported side effects / signs: Follow-up benchmark in Adnexal mass: maintaining LH, FSH & in Adnexal mass (N94.89: Prolactin) within Normal ovulatory endocrine axis (N94.89).
Ask our AI Specialists anything about Adnexal mass
What Is Adnexal mass?
Cataloged under federal diagnostic code N94.89 in OB/GYN & PCOS, Adnexal mass requires minimally invasive gynecologic in Adnexal mass (N94.89: care) so specialists can calibrate treatment intensity against LH, FSH & in Adnexal mass (N94.89: Prolactin) benchmarks.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Adnexal mass (N94.89) features pelvic peritoneal cytokine in Adnexal mass (N94.89: sensitization). therapeutic stabilization in ob/gyn & pcos is verified against Free & Total in Adnexal mass (N94.89: Testosterone + SHBG).
Common Symptoms & Clinical Signs
- • Presentation of Adnexal mass (N94.89): pelvic pressure, bloating, in Adnexal mass (N94.89: or pain radiating)
- • Secondary Adnexal mass clinical sign: irregular, infrequent, or in Adnexal mass (N94.89: absent ovulatory menstrual)
- • Symptom flares in Adnexal mass correlating with LH, FSH & in Adnexal mass (N94.89: Prolactin) deviation outside Normal ovulatory endocrine axis (N94.89)
- • Functional ob/gyn & pcos impact requiring minimally invasive gynecologic in Adnexal mass (N94.89: care) evaluation (N94.89)
Adnexal mass Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | N94.89 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | PCOS, Endometriosis & Gynecologic Health | NLM Clinical Tables |
| Diagnostic / Lab Marker: LH, FSH & in Adnexal mass (N94.89: Prolactin) | Normal ovulatory endocrine axis (N94.89) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Free & Total in Adnexal mass (N94.89: Testosterone + SHBG) | Sex-specific physiological range (N94.89) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Insulin & in Adnexal mass (N94.89: HbA1c) | Fasting insulin < 8 uIU/mL (N94.89) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Adnexal mass
Treatment selection for Adnexal mass depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Adnexal mass)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Effectiveness of myoinositol for polycystic ovary: What a 573-Participant Study Found Based on current evidence, myoinositol may be recommended for the treatment of PCOS with insulin resistance, as well as for improving symptoms caused by decreased estrogen in PCOS. Endocrine • 2018-01-15 • Meta-Analysis | N = 573 | 97/100 | PMID 29052180 ↗ |
| Can This Approach Help? Inside the Latest Research on Onset and resolution of ovarian toxicity with nirogacestat treatment in females Most FORP treated with nirogacestat experienced OT, with the majority resolving, including all who stopped treatment, suggesting that OT is transient. Cancer • 2024-08-15 • Phase III Randomized Trial | N = 36 | 88/100 | PMID 38703010 ↗ |
| Can This Approach Help? Inside the Latest Research on Urinary human follicle-stimulating hormone and human menopausal gonadotropin for The size of the material does not permit a comparison of the efficacy of the two treatment schedules. Fertility and sterility • 1990-03-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 2106449 ↗ |
| New Insights on Contribution of contrast-enhanced ultrasound for diagnosis of adnexal torsion: What a 256-Participant Study Found The ethical approval number from the CPP is 6115. BMJ open • 2026-02-25 • Phase III Randomized Trial | N = 256 | 87/100 | PMID 41748169 ↗ |
| Can This Approach Help? Inside the Latest Research on Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing The small, but significant, increase in serum E2 after hCG stimulation suggests that a rigid two-cell model of ovarian steroidogenesis may be an oversimplification of in vivo physiology. The Journal of clinical endocrinology and metabolism • 1996-11-15 • Randomized Controlled Trial | Multi-cohort | 82/100 | PMID 8923867 ↗ |
Adnexal mass Patient Community & “People Like Me” Threads
Filter Adnexal mass community threads and patient logs by age, biological sex, dosage, and treatment duration.